PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Similar documents
PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA First Exam. Fall 2004

PHA First Exam Fall 2003

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA Final Exam Fall 2006

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA 5127 FINAL EXAM FALL On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA First Exam Fall 2013

PHA5128 Dose Optimization II Case Study I Spring 2013

Renal Function. 1. Glomerular filtration 2. Active tubular secretion 3. Passive tubular reabsorption 4. Excretion

PHA Final Exam Fall 2001

PHA Spring First Exam. 8 Aminoglycosides (5 points)

PHA 5128 Spring 2000 Final Exam

BASIC PHARMACOKINETICS

PHA 5128 Spring 2009 First Exam (Version B)

General Principles of Pharmacology and Toxicology

General Principles of Pharmacology and Toxicology

Drug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila

PHA 5128 Final Exam Spring 2004 Version A. On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Excretion of Drugs. Prof. Hanan Hagar Pharmacology Unit Medical College

You should know the T max for any substance that you use and for PAH ; T max = mg / min

Renal Clearance. Dr. Eman El Eter

Basic Concepts in Pharmacokinetics. Leon Aarons Manchester Pharmacy School University of Manchester

TDM. Measurement techniques used to determine cyclosporine level include:

Renal Physiology. April, J. Mohan, PhD. Lecturer, Physiology Unit, Faculty of Medical Sciences, U.W.I., St Augustine.

LD = (Vd x Cp)/F (Vd x Cp)/F MD = (Css x CL x T)/F DR = (Css x (Vm-DR))/Km Css = (F x D)/(CL x T) (Km x DR)/(Vm DR)

Renal Impairment From Dettli to Guideline: What can we learn?

Filtration and Reabsorption Amount Filter/d

One-Compartment Open Model: Intravenous Bolus Administration:

PHA 4120 Second Exam Key Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Name: UFID: PHA Exam 2. Spring 2013

Introduction to Pharmacokinetics (PK) Anson K. Abraham, Ph.D. Associate Principal Scientist, PPDM- QP2 Merck & Co. Inc., West Point, PA 5- June- 2017

Nontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment

Basic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy

BIOPHARMACEUTICS and CLINICAL PHARMACY

Renal Excretion of Drugs

The kidney. (Pseudo) Practical questions. The kidneys are all about keeping the body s homeostasis. for questions Ella

Determination of bioavailability

PHA 5128 CASE STUDY 5 (Digoxin, Cyclosporine, and Methotrexate) Spring 2007

BIOL 2402 Renal Function

PHAR 7632 Chapter 16

Metformin Associated Lactic Acidosis. Jun-Ki Park 9/6/11

we usually use PAH - a substance called para-amino-hippouric acid to measure Clearance because it has the following characteristics :

Pharmacokinetics in the critically ill. Intensive Care Training Program Radboud University Medical Centre Nijmegen

= (6000 ml air / min * 0.04 ml CO 2 / ml air) / 54 ml CO 2 / dl plasma

Lecture-2 Review of the previous lecture:

The general Concepts of Pharmacokinetics

Applied Biopharmaceutics & Pharmacokinetics Sixth Edition

Introduction to Clinical Diagnosis Nephrology

Assessing Renal Function: What you Didn t Know You Didn t Know

Section 5.2: Pharmacokinetic properties

Estimation of Serum Creatinine, Urine Creatinine and Creatinine Clearance. BCH472 [Practical] 1

ADME Review. Dr. Joe Ritter Associate Professor of Pharmacology

Physiology questions review

TDM Lecture 7 5 th Stage. TDM of Digoxin. Uses: Digoxin is usually used in heart failure associated and atrial fibrillation.

BCH 450 Biochemistry of Specialized Tissues

1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?

Drug elimination and Hepatic clearance Chapter 6

PHARMACOKINETICS SMALL GROUP II:

Rational Dose Prediction. Pharmacology. φαρμακον. What does this mean? pharmakon. Medicine Poison Magic Spell

Chapter 23. Composition and Properties of Urine

Pharmacokinetics in Drug Development. Edward P. Acosta, PharmD Professor & Director Division of Clinical Pharmacology Director, CCC PK/PD Core

Renal Function and Associated Laboratory Tests

Lippincott Questions Pharmacology

Pharmacokinetics of Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Click to edit Master title style

Monica Edholm Medica Medic l a Pr oducts Agency

Glomerular filtration rate (GFR)

CLINICAL PHARMACOKINETICS INDEPENDENT LEARNING MODULE

ANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO

Unit 2b: EXCRETION OF DRUGS. Ms.M.Gayathri Mpharm (PhD) Department of Pharmaceutics Krishna Teja Pharmacy college Subject code: 15R00603 (BPPK)

Understand the physiological determinants of extent and rate of absorption

Pharmacokinetics One- compartment Open Model Lec:2

ZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN

Acknowledgements. National Kidney Foundation of Connecticut Mark Perazella. Co-PI Slowing the progression of chronic kidney disease to ESRD

Introduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

The ADME properties of most drugs strongly depends on the ability of the drug to pass through membranes via simple diffusion.

LECTURE 25: FILTRATION AND CLEARANCE NEPHRON FILTRATION

NIH Public Access Author Manuscript Transplant Proc. Author manuscript; available in PMC 2010 September 22.

Chapter-V Drug use in renal and hepatic disorders. BY Prof. C.Ramasamy, Head, Dept of Pharmacy Practice SRM College of Pharmacy, SRM University

C OBJECTIVES. Basic Pharmacokinetics LESSON. After completing Lesson 2, you should be able to:

Effects of Liver Disease on Pharmacokinetics

Nephron Function and Urine Formation. Ms. Kula December 1, 2014 Biology 30S

CRRT and Drug dosing. Karlee Johnston Lead Pharmacist Division of Critical Care ICU Education June 2017

RENAL SYSTEM 2 TRANSPORT PROPERTIES OF NEPHRON SEGMENTS Emma Jakoi, Ph.D.

Basic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations

Terminology. Terminology. Terminology. Molarity number of moles of solute / Liter of solution. a) Terminology b) Body Fluid Compartments

Policy: Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing

Pharmacokinetics Overview

BCH472 [Practical] 1

Functional morphology of kidneys Clearance

Pharmacokinetic parameters: Halflife

PRESCRIBING IN LIVER AND RENAL DISEASE

Renal-Related Questions

UNIVERSITY OF THE WEST INDIES, ST AUGUSTINE

Renal Disease and PK/PD. Anjay Rastogi MD PhD Division of Nephrology

MODULE 8: URINALYSIS AND ACID BASE BALANCE

Transcription:

PHA 5127 Second Exam Fall 2012 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet TOTAL /150 pts 1

Question Set I (True or False) (15 points) True (A) or False (B). On the bubble sheet mark A for true or B for false Mark whether the following statements are true (A) or false (B). Mark false if there is not sufficient information given to provide answer. Differences should be of clinical significance, otherwise state F. The lipophilic drug A (neither an acid nor a base) is cleared only by hepatic metabolism, crosses membranes quite easily, and dissolves in the GI tract. When given to Patient A, it has a f u of 0.9, and an intrinsic clearance of 300,000 L/h. Patient B has a fraction unbound of 0.99; the only difference to Patient A. 1. T F The oral bioavailability of this drug is higher in Patient B. 2. T F The AUC of plasma concentration vs time curve in Patient B after iv bolus injection is higher than when the same dose is given as iv bolus to Patient A. 3. T F The C max after iv bolus injection is lower in patient A when the same dose is given as iv bolus injection. 4. T F Decrease in tissue binding will affect the AUC 0-inf in both Patient A and B. 5. T F Increase in liver blood flow will affect the half-life of the drug in both patients. 2

Question Set II (16 points) A patient participated in a clinical study. The patient receives first 100mg IV bolus dose of Alprazolam (Scenario 1) The patient then receives 100mg IV bolus Alprazolam+50mg IV bolus Carbamezapine (Scenario 2). The plasma concentration time profiles of Alprazolam in scenario 1 and scenario 2 are shown in the figure below. Please provide a qualitative comparison (A: greater than, B: lesser than B; or C equal to) of following parameters 6) Clearance of the patient in scenario 1 is. that of the patient in scenario 2 7) Volume of Distribution of the patient in scenario 1 is. that of the patient in scenario 2 8) Initial drug concentration (C max ) of the patient in scenario 1 is. that of the patient in scenario 2 9) If the drug regimens are given orally, the oral bioavailability of alprazolam given alone (Scenario 1) is. that of alprazolam+50 mg carbamezepine (scenario 2) 3

Question Set III True (A) or False (B). On the bubble sheet mark A for true or B for false (24 points) A new analysis technique has enabled you to measure the drug concentration before and after the blood passes through the liver. The plasma concentrations before and after the liver was passed were 1.0 and 0.95 mg/ml, respectively. Consider that differences should be clinically significant. 10) T F The drug is a low extraction drug 11) T F The oral bioavailability will be low 12) T F The oral bioavailability will depend on the liver blood flow 13) T F Clearance will depend on tissue protein binding True (A) or False (B). On the bubble sheet mark A for true or B for false Mark whether the following statements are true (A) or false (B). Mark false if there is not sufficient information given to provide answer. Assume a drug which is eliminated through hepatic metabolism only. 14) T F A change in the intrinsic clearance will affect the volume of distribution 15) T F Intrinsic clearance and volume of distribution are independent of each other 16) T F If the drug is a high extraction drug, enzyme induction of the relevant enzyme will affect the hepatic clearance. 17) T F For a low extraction drug, changes in plasma protein binding will affect either volume of distribution or hepatic clearance, as Vd and CL are independent parameters. 4

Question Set IV (10 points) 18) A 59 year-old white male patient is hospitalized for a ruptured duodenal diverticulum. Before surgery you are asked to begin this patient on aminoglycosides. Other pertinent patient data are: height 5ft, 1in; weight 65kg, serum creatinine 1.3mg/dl. Please estimate the clearance of this patient. A) 56.3 ml/min B) 39.3 ml/min C) 3 L/h D) 3 ml/min E) 3.8 L/h 5

Question Set V (15 point) True (A) or False (B). On the bubble sheet mark A for true or B for false Mark false if there is not sufficient information provided to answer the question. The lipophilic drug A, neither an acid nor base, is completely dissolved in the GI tract, crosses membranes easily, and is cleared only via the kidneys, and is not subject to transporter-mediated processes. 19) T F The oral bioavailability of drug A is likely to be large. 20) T F Plasma protein binding will affect the oral bioavailability of this drug. 21) T F It is unlikely that the renal clearance of this drug is affected by drug-druginteractions. 22) T F Changes in liver blood flow will significantly alter the clearance of drug A. 23) T F The renal clearance of this drug is close to renal blood flow. 6

Question Set V (30 points) A lipophilic acidic drug (pka = 13.9) is only renally eliminated, is 75% plasma protein bound, and crosses membranes easily in its unionized form. The patient taking this drug has a normal glomerular filtration rate and a urine flow of 1.8mL/min. The ph of the urine is similar to that in blood. The drug s volume of distribution was determined as 50L. 24) Which of the following values describes best the clearance of this drug? (15 pts) A) 130mL/min B) 32.5mL/min C) 0.45mL/min D) 16.25mL/min E) 0.23mL/min 25. The same drug is given at the same dose to two patients as a single intravenous bolus. These patients only differ in their ability to eliminate the drug from the system (Clren differs). Select the answer that lists all the pharmacokinetic parameters that differ between these two patients? (15 pts) A) Peak concentrations and clearance B) Half-life C) AUC D) Half-life and AUC E) Half-life and volume of distribution 7

Question Set VI (20 points) You receive a call from your emergency room physician saying he has a number of patients in the ER that overdosed on the following five drugs (1-5). Which of the methods A-E would you recommend to your physician to help his patients? Please select the single best choice for detoxification for drugs 1-5 from the list below. A) Adjust urine ph B) Increase urine flow C) Give drug that induces liver enzymes D) Perform dialysis as nothing else works E) None of the above 26. Drug 1 is eliminated primarily via the liver (high extraction drug) 27 Drug 2 is lipophilic (nor acid or base) and is only eliminated via the kidneys 28. Drug 3, a lipophilic acid (pk a = 7.4), is solely eliminated via the kidneys 29. Drug 4, a lipophilic unionized drug is solely eliminated via the kidneys 30. Drug 5 is eliminated primarily via the liver (low extraction drug) 8

Question Set VII (20 points) Assume GFR is 130mL/min, urine flow is 1.8mL/min. For the following situation, indicate whether the drug is: A) Only filtered B) Passively reabsorbed C) Actively secreted D) Actively reabsorbed Question 31: A drug with fu = 0.3 and Clren = 0.54 ml/min Question 32: A drug with fu = 0.6 and Clren = 0.2 ml/min Question 33: A drug with fu = 0.25 and Clren = 32.5 ml/min Question 34: A drug with fu = 0.2 and Clren = 32.5mL/min 9